Clinical Trial Update: Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating rituximab, temozolomide, and methylprednisolone for recurrent primary CNS non-Hodgkin's lymphoma; the study is terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)
• Rituximab (rituximab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-09-04